Liquidia Technologies, Inc. (LQDA) shares soared 11.2% in the last trading session to close at $11.15. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.3% gain over the past four weeks. The sudden rise in the stock price was observed after the United States Supreme Court ruled in favour of Liquidia stating that its pulmonary hypertension treatment powder, Yutrepia, does not infringe upon United Therapeutics' '793 Patent for Tyv ...

Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere Liquidia also obtains rights to Pharmosa's next-generation nebulizers for use with L606 Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America MORRISVILLE, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare ...

MORRISVILLE, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians on October 6-9, 2024, in Boston. Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: "Every year, CHEST unites the next generation of medical p ...

MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by United Therapeutics Corporation (United Therapeutics) with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil Injection is ...

Liquidia Technologies, Inc. (LQDA) shares rallied 14.1% in the last trading session to close at $10.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 33% loss over the past four weeks. The sudden rise in the stock price was observed after Liquidia announced the pricing of an underwritten public offering and a concurrent private placement which is expected to raise gross proceeds of approximately $67.5 milli ...

MORRISVILLE, N.C., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (the "Company" or "Liquidia"), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the pricing of an underwritten public offering and a concurrent private placement, with anticipated total gross proceeds of approximately $67.5 million, before deducting underwriting discounts and commissions, and expenses. The Company offered 6,460,674 shares of co ...

MORRISVILLE, N.C., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the following investor conferences this September: 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, from 11:00 – 11:35 a.m. ET 2024 Cantor Global Healthcare Conference in New York on Thursday, September 19, 2024, from 1:30 – 1:50 p.m ...

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) on behalf of Liquidia stockholders. Our investigation concerns whether Liquidia has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 19, 2024, Liquidia issued a press release announcing ...

NEW YORK, Aug. 26, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Liquidia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 19, 2024 ...

MORRISVILLE, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it has filed litigation in the U.S. District Court of the District of Columbia (Case No. 1:24- cv-02428) that challenges the recent decision by the United States Food and Drug Administration (FDA) to grant 3-year new clinical investigation exclusivity (NCI exclusivity) to Tyvaso DPI®. FDA gra ...